Corporis Medical

Corporis Medical is a Dutch startup established in 2014, concentrating on pioneering and commercializing revolutionary surgical devices. Founded by Dr. Alexander Veenhof, a specialized oncologic surgeon at the NKI-AvL, the company draws inspiration from his experiences in the operating room. Currently, Corporis Medical is dedicated to introducing two groundbreaking devices to the market: Laprixa™ and Mediclose™. Laprixa™, the world’s smallest tissue blood pressure measuring device, serves to provide surgeons with a patient-specific, quantitative, objective, and intraoperative prediction of the wound healing capacity of bowel tissue during an anastomosis. This capability plays a crucial role in preventing life-threatening complications such as anastomotic leakage. On the other hand, Mediclose™ addresses the challenging closure of the essential fascia layer in the patient’s abdominal wall after laparoscopic surgery. The automatic trocar closure device aims to ensure safer and more effective closure of trocar-induced wounds, reducing the risk of potential dangerous complications. Notably, Corporis Medical secured a €4.00M Series B investment as of 07 December 2023 from investors including Unorthodox Ventures, NV Industriebank LIOF, and Brightlands Venture Partners. The company's innovative approach and the potential impact of its devices on enhancing surgical outcomes make it an intriguing prospect for venture capital investment.